Dilaforette, Ergomed deal

Dilaforette will pay Ergomed an undisclosed sum to conduct an international Phase II trial of Dilaforette’s sevuparin to treat vaso-occlusive crisis (VOC) in patients with sickle cell disease. Ergomed...